AZN Stock Recent News

Anglo-Swedish drugmaker AstraZeneca on Friday said its inhaler therapy Breztri Aerosphere met all the main goals of two late-stage trials in patients with uncontrolled asthma.

AstraZeneca PLC (LSE:AZN) investors looking beyond the short-term noise of Medicare reform and currency headwinds may want to focus on a growing pipeline of clinical catalysts and a valuation that UBS believes underplays the company's longer-term potential. The bank retains its 'buy' rating with a price target of 14,200p, offering more than 30% upside from the current share price of around 10,600p.

AstraZeneca CEO Pascal Soriot discusses earnings, the potential trade tariff impact on the business and the outlook for the firm's key markets.

Jimmy Muchechetere, senior equity analyst at Investec, weighs in on the prospect of pharmaceutical tariffs and recent U.S. investment commitments from the sector.

AstraZeneca PLC (NASDAQ:AZN ) Q1 2025 Earnings Conference Call April 29, 2025 6:45 AM ET Company Participants Andy Barnett - Head of IR Pascal Soriot - Executive Director and CEO Aradhana Sarin - Executive Director and CFO Dave Fredrickson - EVP, Oncology Business Unit Susan Galbraith - EVP, Oncology R&D Ruud Dobber - EVP, BioPharmaceuticals Business Unit Sharon Barr - EVP, BioPharmaceuticals R&D Marc Dunoyer - CEO, Alexion Iskra Reic - EVP, International Conference Call Participants Sarita Kapila - Morgan Stanley James Gordon - JPMorgan Rajan Sharma - Goldman Sachs? Sachin Jain - Bank of America Steve Scala - Cowen Mattias Haggblom - Handelsbanken Matthew Weston - UBS Justin Smith - Bernstein Seamus Fernandez - Guggenheim Simon Baker - Redburn Rajesh Kumar - HSBC Luisa Hector - Berenberg Peter Verdult - BNP Operator Good morning to those joining from the UK and the U.S. Good afternoon to those in Central Europe and good evening to those listening in Asia.

AstraZeneca (AZN) reported mixed first quarter earnings results, missing on revenue estimates but beating on earnings per share (EPS). The company also reaffirmed its 2025 outlook and has highlighted its commitment to US investments amid tariff concerns.

After an early stumble, AstraZeneca PLC (LSE:AZN) shares pulled back to level by the close on Tuesday, but analysts see reasons for investors to stay watchful despite the apparent strength of the results. At face value, the update looked reassuring.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

The headline numbers for Astrazeneca (AZN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

AstraZeneca reports mixed first-quarter 2025 results. The fall in pre-market is likely due to the soft sales performance of key drugs across the oncology and rare disease segments.